Fatigue is one of the most common complaints in medicine — and one of the most nonspecific. It can reflect poor sleep, stress, anemia, thyroid disease, depression, or simply the ordinary demands of a busy life. But fatigue is also a central symptom of many forms of heart disease, and cardiac fatigue has distinct characteristics that differentiate it from ordinary tiredness. Understanding the mechanisms by which heart disease produces fatigue, which cardiac conditions most commonly cause it, and when unexplained fatigue should prompt evaluation for a cardiac cause can help patients and physicians identify heart disease that might otherwise go undetected.
How Heart Disease Causes Fatigue
The common thread running through cardiac fatigue is reduced delivery of oxygen and nutrients to the body’s tissues. When the heart fails to pump effectively — whether from reduced contractility, impaired filling, a rhythm problem, or a structural abnormality — the muscles and organs receive less blood per minute than they need. At rest, this may produce mild fatigue. During physical activity, when oxygen demand increases but the heart cannot meet that demand, fatigue occurs earlier and more severely.
Several mechanisms contribute beyond simple reduced cardiac output. Chronic heart failure triggers the release of inflammatory cytokines — tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) — that directly impair skeletal muscle function and contribute to a central fatigue that patients describe as heaviness, lack of motivation, and difficulty initiating activity. This is distinct from the breathlessness that comes from pulmonary congestion and explains why some heart failure patients complain primarily of fatigue rather than dyspnea.
Skeletal muscle deconditioning worsens cardiac fatigue through a vicious cycle: patients with heart disease reduce their activity because it is uncomfortable, their skeletal muscles decondition from inactivity, and the same workload now requires more cardiac output and feels harder. Anemia — common in heart failure, present in up to 50 percent of hospitalized heart failure patients — reduces the oxygen-carrying capacity of the blood, amplifying the fatigue from reduced cardiac output. Sleep-disordered breathing (particularly obstructive sleep apnea, which is strongly associated with heart disease) disrupts restorative sleep and adds daytime fatigue on top of the hemodynamic fatigue. And depression — present in 15 to 40 percent of patients with heart failure — produces fatigue, low motivation, and reduced physical activity that are difficult to distinguish from the cardiac component without careful assessment.
Heart Failure: The Most Common Cardiac Cause
Heart failure is the cardiac condition most strongly and consistently associated with fatigue. In heart failure with reduced ejection fraction (HFrEF), the left ventricle’s pumping function is impaired, reducing stroke volume and cardiac output. The body compensates through sympathetic activation (increasing heart rate), fluid retention (increasing preload), and peripheral vasoconstriction — but these compensatory mechanisms eventually become insufficient, and the symptoms of low cardiac output emerge: fatigue, dyspnea, and exercise intolerance.
Heart failure with preserved ejection fraction (HFpEF) — where the ejection fraction is preserved (above 50 percent) but the ventricle fills abnormally due to stiffness — produces identical symptoms despite different physiology. The stiff ventricle cannot accommodate increased venous return during exercise, causing elevated filling pressures, pulmonary congestion, and fatigue. HFpEF is particularly common in older women, patients with obesity, hypertension, and diabetes, and is increasingly recognized as the dominant form of heart failure in older adults.
The New York Heart Association (NYHA) functional classification describes the relationship between activity and heart failure symptoms: Class I patients have no symptoms with ordinary activity; Class II patients develop symptoms with moderate exertion; Class III patients are symptomatic with minimal exertion; Class IV patients have symptoms at rest. Fatigue tracks closely with this classification and is a key outcome measure in heart failure trials.
Coronary Artery Disease and Fatigue
In coronary artery disease, fatigue can be a primary presenting symptom rather than chest pain — particularly in women and diabetic patients, who are more likely to experience “atypical” angina presentations. Exertional fatigue as an anginal equivalent reflects transient myocardial ischemia during exertion: when a coronary stenosis limits blood flow to a region of myocardium during increased demand, the affected muscle contracts less effectively, reducing overall cardiac output and producing fatigue rather than (or in addition to) chest pain.
Acute myocardial infarction is associated with profound fatigue in the acute and recovery phases. The loss of functional myocardium reduces the heart’s pumping capacity immediately, and the inflammatory response of myocardial injury produces systemic fatigue through cytokine release. Post-MI fatigue can persist for weeks to months as the heart remodels and recovers. Depression, which affects up to 30 percent of patients after myocardial infarction, contributes significantly to post-MI fatigue and must be actively addressed as part of cardiac rehabilitation.
Arrhythmias and Valvular Heart Disease
Cardiac arrhythmias cause fatigue by reducing the efficiency of cardiac output. Atrial fibrillation with a rapid ventricular response — heart rates above 100 to 120 beats per minute — reduces diastolic filling time and impairs the atrial contribution to ventricular filling, reducing stroke volume. The irregular rhythm further reduces efficiency. Bradycardia — heart rates too slow to maintain adequate cardiac output — produces fatigue through a different mechanism: insufficient beats per minute rather than insufficient volume per beat.
Among valvular conditions, aortic stenosis classically produces the symptom triad of angina, syncope, and dyspnea or fatigue as the valve narrows progressively. Severe aortic stenosis — valve area below 1 cm² — markedly limits forward flow and produces exertional fatigue, dyspnea, and reduced exercise tolerance. Mitral regurgitation creates chronic volume overload of the left ventricle; over years, the ventricle dilates and its function declines, producing fatigue and dyspnea that reflect the transition from compensated to decompensated regurgitation.
Fatigue as a Warning Sign in Women
The association between fatigue and heart disease deserves particular emphasis in women, where it serves as an early warning sign that is frequently overlooked or attributed to non-cardiac causes. Research from the WISE (Women’s Ischemia Syndrome Evaluation) study demonstrated that women with coronary artery disease and myocardial ischemia frequently present with atypical symptoms — fatigue, weakness, sleep disturbance, and general malaise — rather than the classic exertional chest pain that is more typical in men.
In the context of acute myocardial infarction, up to 70 percent of women report unusual fatigue in the weeks preceding the event — a prodromal symptom that is often interpreted as stress, overwork, or viral illness before the coronary event clarifies its cardiac origin. This recognition gap — women’s cardiac fatigue being attributed to non-cardiac causes while cardiac evaluation is delayed — contributes to the well-documented gap in timely diagnosis and treatment of coronary artery disease in women.
Clinicians evaluating unexplained fatigue in middle-aged and older women should maintain a lower threshold for cardiac evaluation, particularly in the presence of cardiac risk factors (hypertension, diabetes, family history, smoking, obesity). A BNP or NT-proBNP level, resting ECG, and echocardiogram are reasonable initial steps when cardiac fatigue is suspected.
Overlapping Non-Cardiac Causes
Several non-cardiac conditions that cause fatigue commonly coexist with heart disease and must be systematically evaluated alongside the cardiac work-up. Anemia — from iron deficiency, renal disease-related reduction in erythropoietin, or chronic disease — is extremely common in heart failure patients and independently worsens fatigue and exercise tolerance. Hypothyroidism reduces cardiac function and independently causes fatigue; TSH testing should be routine in the fatigue evaluation. Obstructive sleep apnea is present in 30 to 50 percent of heart failure patients and contributes substantially to daytime fatigue through sleep disruption; treatment with CPAP improves fatigue, cardiac function, and quality of life. Depression is both a consequence of and a contributor to cardiac fatigue, and its prevalence in heart disease populations (15 to 40 percent) demands active screening and treatment.
How Cardiac Fatigue Is Different
Several features help distinguish cardiac fatigue from other causes. Cardiac fatigue follows an exertional pattern — it is worse with physical activity and improves with rest, though in advanced heart failure it may be present at rest. It is often accompanied by dyspnea — shortness of breath with exertion, orthopnea (breathlessness when lying flat), or paroxysmal nocturnal dyspnea (awakening from sleep with breathlessness). It may be accompanied by ankle swelling, weight gain from fluid retention, and abdominal fullness from right heart congestion. Cardiac fatigue is typically not relieved by additional sleep alone — a night of adequate rest does not restore normal energy levels as it would with simple tiredness — and it tends to worsen progressively over days to weeks when heart failure is decompensating.
Evaluating Fatigue With a Possible Cardiac Cause
When cardiac fatigue is suspected, evaluation begins with a focused history and physical examination. The BNP (B-type natriuretic peptide) or NT-proBNP blood test is an excellent screening tool for heart failure: elevation above established thresholds has high sensitivity for significant cardiac dysfunction. A 12-lead ECG identifies arrhythmias, prior MI, and left ventricular hypertrophy that suggest cardiac disease. An echocardiogram evaluates ejection fraction, valvular function, wall motion, and diastolic function — the most informative single test for characterizing the cardiac cause of fatigue. Complete blood count screens for anemia; TSH for thyroid dysfunction; and basic metabolic panel for renal function, which is frequently impaired in chronic heart failure.
Exercise stress testing can identify inducible ischemia (in patients with suspected coronary artery disease) and assess chronotropic competence — the heart’s ability to appropriately increase its rate during exercise. Patients with chronotropic incompetence experience disproportionate fatigue because their heart rate does not rise adequately to meet the increased oxygen demand of activity, limiting cardiac output during exertion despite normal resting function.
Treatment: Addressing the Cardiac Cause
Treatment of cardiac fatigue centers on addressing the underlying cardiac condition. For heart failure with reduced ejection fraction (HFrEF), guideline-directed medical therapy (GDMT) — comprising ACE inhibitors or angiotensin receptor blockers, beta-blockers, SGLT2 inhibitors, and mineralocorticoid receptor antagonists — significantly reduces fatigue and improves exercise capacity alongside the established mortality and hospitalization benefits. Each of these drug classes addresses a different aspect of the neurohormonal dysfunction that drives heart failure progression and its symptoms.
Iron deficiency is extremely common in HFrEF and independently worsens fatigue even in the absence of frank anemia. The FAIR-HF and AFFIRM-AHF trials demonstrated that intravenous iron supplementation in iron-deficient HFrEF patients significantly improves exercise capacity, symptoms, and quality of life. Oral iron is poorly absorbed in heart failure; intravenous formulations are preferred when iron deficiency is documented.
Cardiac rehabilitation — structured, supervised exercise training combined with education and psychological support — is one of the most effective interventions for cardiac fatigue. Regular aerobic exercise breaks the deconditioning cycle, improves skeletal muscle efficiency, reduces sympathetic tone, and substantially improves functional capacity and quality of life in both heart failure and post-MI patients. The benefits extend beyond exercise: cardiac rehabilitation programs address the depression, anxiety, and lifestyle factors that amplify cardiac fatigue.
Sleep apnea treatment with CPAP improves daytime fatigue and, in patients with heart failure, contributes to improved cardiac function. Depression in heart disease patients responds to selective serotonin reuptake inhibitors (SSRIs) and cognitive behavioral therapy (CBT), with exercise playing a beneficial role in both depression and cardiac function. Treating all contributing factors — not just the primary cardiac diagnosis — produces the most meaningful improvement in energy and functional status.
For understanding breathing changes that accompany cardiac fatigue, see our article on shortness of breath and heart health. For the broader set of cardiovascular measurements relevant to heart disease monitoring, see heart health numbers every adult should know. For context on how heart rate changes with cardiac conditions, see our article on what resting heart rate is.
The American Heart Association provides information on the warning signs of heart failure including fatigue. The NIH National Heart, Lung, and Blood Institute explains heart failure symptoms and when to seek evaluation. The CDC provides epidemiological data on heart failure as a major public health condition.
Fatigue is the great masquerader in cardiac medicine. Taken in isolation, it provides little diagnostic signal — almost anything can cause fatigue. But in context — alongside dyspnea, edema, cardiac risk factors, or a new onset in a patient with known heart disease — it becomes one of the most important symptoms to pursue systematically. Early identification of cardiac fatigue and treatment of its cause — whether heart failure, arrhythmia, or ischemia — can substantially improve both quality of life and long-term cardiac outcomes.
Cardiomyopathy and Pericardial Disease
Beyond heart failure from ischemic or hypertensive causes, several primary myocardial and pericardial conditions produce significant fatigue. Dilated cardiomyopathy — dilation and reduced contractility of the left ventricle from viral myocarditis, alcohol, chemotherapy agents such as anthracyclines, or genetic mutations — reduces cardiac output and causes fatigue that is clinically indistinguishable from ischemic HFrEF. The fatigue in dilated cardiomyopathy can be severe; patients frequently report difficulty completing previously routine tasks such as climbing stairs or carrying groceries, and the transition from asymptomatic ventricular dysfunction to overt heart failure can be marked by a rapid escalation in fatigue severity.
Hypertrophic cardiomyopathy (HCM) produces fatigue through a different mechanism. The thickened, hypertrophied left ventricle has impaired diastolic relaxation and, in patients with outflow tract obstruction, generates a dynamic gradient that limits forward stroke volume with exertion. Fatigue during physical activity in HCM can be the predominant complaint, sometimes preceding any awareness of the underlying cardiac diagnosis. In HCM, fatigue is often accompanied by dyspnea and occasionally by lightheadedness or presyncope with exertion — symptoms that should always prompt cardiac evaluation in younger patients.
Cardiac amyloidosis — infiltration of the myocardium by amyloid fibrils — produces a stiff, restrictive ventricle that cannot fill adequately and generates fatigue through severely impaired diastolic function. Transthyretin amyloid cardiomyopathy (ATTR-CM), the more common form in older adults, is increasingly recognized as a cause of heart failure and fatigue in patients over 65 with HFpEF physiology, particularly in men. Pericardial effusion and constrictive pericarditis impair cardiac filling from outside the myocardium, producing fatigue, dyspnea, and exercise intolerance through extrinsic compression of the heart’s filling chambers.
Fatigue After Cardiac Procedures and Surgery
Many patients experience significant fatigue in the weeks following cardiac interventions, including percutaneous coronary intervention (PCI), cardiac ablation, valve repair or replacement surgery, and coronary artery bypass grafting (CABG). Post-surgical fatigue following open heart surgery reflects the combined effects of general anesthesia, the inflammatory response to surgery, cardiopulmonary bypass (when used), perioperative anemia from blood loss, pain-related sleep disruption, and the psychological adjustment to a major cardiac event. Fatigue after CABG typically peaks in the first two to four weeks and gradually resolves over two to three months, though some patients experience more persistent fatigue, particularly those with pre-existing depression or deconditioning.
Fatigue after catheter ablation for atrial fibrillation or ventricular arrhythmias is common in the first one to two weeks, often related to the inflammatory response at ablation sites, anesthesia effects, and the exertion of the procedure itself. Valve surgery patients typically follow a similar recovery trajectory to CABG, with fatigue improving as the myocardium adapts to normalized loading conditions following valve repair or replacement. Cardiac rehabilitation beginning four to six weeks after surgery plays a critical role in accelerating functional recovery and reducing post-procedural fatigue.
When to Seek Evaluation for Unexplained Fatigue
Not every patient with fatigue needs a cardiac evaluation, but certain features should prompt more urgent assessment. Fatigue accompanied by dyspnea — particularly dyspnea with activities that were previously well tolerated, or dyspnea when lying flat — significantly raises the probability of a cardiac cause and warrants prompt evaluation. Fatigue combined with ankle swelling, rapid weight gain (more than two to three pounds in 24 to 48 hours), or abdominal bloating suggests fluid retention from heart failure decompensation. Fatigue with palpitations, near-syncope, or brief episodes of lightheadedness raises the possibility of an arrhythmia driving reduced cardiac output. Chest discomfort with exertion that is accompanied by fatigue may represent an anginal equivalent in a patient with underlying coronary disease.
New, unexplained fatigue in a patient with established cardiac disease — known heart failure, prior MI, significant valvular disease, or a cardiomyopathy — always warrants evaluation because it may signal disease progression or decompensation. A repeat BNP or NT-proBNP measurement can rapidly clarify whether fatigue reflects worsening heart failure; a significantly elevated or rising value compared to a previous baseline strongly supports a cardiac cause and the need for medication adjustment or further evaluation.
Frequently Asked Questions
Can heart disease cause fatigue without any chest pain?
Yes, and this is one of the most important aspects of cardiac fatigue to understand. Many patients with heart failure, arrhythmias, and even coronary artery disease experience fatigue as their predominant symptom without significant chest pain. This is especially common in women, older adults, and patients with diabetes, who may have altered pain perception. Fatigue without chest pain does not rule out a cardiac cause, and the absence of chest pain should not delay cardiac evaluation when other cardiac features (dyspnea, edema, exertional intolerance) are present.
How is cardiac fatigue different from depression-related fatigue?
Both cardiac and depression-related fatigue can coexist in the same patient, making distinction difficult. Cardiac fatigue tends to follow an exertional pattern — worse with activity, somewhat improved with rest — and is accompanied by dyspnea, fluid retention, or palpitations. Depression-related fatigue is often accompanied by low mood, anhedonia (loss of pleasure), sleep disturbance in the form of early morning waking, and cognitive symptoms (difficulty concentrating). Because depression is extremely common in heart disease patients, both contributors are often present simultaneously and both require treatment for optimal improvement in fatigue and quality of life.
Does treating heart failure improve fatigue?
Guideline-directed therapy for heart failure consistently improves fatigue and exercise capacity as part of its broader benefit. ACE inhibitors, beta-blockers, SGLT2 inhibitors, and mineralocorticoid receptor antagonists all reduce symptoms, including fatigue, in patients with HFrEF. SGLT2 inhibitors have shown particularly notable benefit on quality-of-life measures including fatigue even at relatively early time points in trials. Cardiac rehabilitation is one of the most effective fatigue interventions available, with multiple trials showing substantial improvement in functional capacity and patient-reported fatigue scores.
Can fatigue from heart disease improve without surgery?
In most cases, yes. Medical therapy for heart failure, arrhythmia control, and cardiac rehabilitation can substantially reduce fatigue from cardiac causes without surgical intervention. Procedural or surgical intervention becomes necessary for specific conditions — severe aortic stenosis requiring valve replacement, coronary artery disease requiring revascularization, or refractory arrhythmias requiring ablation — where the structural or electrical problem driving fatigue cannot be adequately addressed medically. For heart failure, the introduction of guideline-directed medical therapy often produces meaningful improvement in fatigue within weeks to months of treatment initiation.